Open AccessDNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age
Author(s) -
Kim HaNeui,
Chang Jianhui,
Shao Lijian,
Han Li,
Iyer Srividhya,
Manolagas Stavros C.,
O'Brien Charles A.,
Jilka Robert L.,
Zhou Daohong,
Almeida Maria
Publication year - 2017
Publication title -
aging cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.103
H-Index - 140
eISSN - 1474-9726
pISSN - 1474-9718
DOI - 10.1111/acel.12597
Subject(s) - senescence , osteoblast , biology , progenitor cell , osteoclast , stromal cell , bone marrow , bone resorption , microbiology and biotechnology , mesenchymal stem cell , endocrinology , osteoprotegerin , medicine , cancer research , immunology , stem cell , in vitro , genetics , gene , activator (genetics)
Summary Age‐related bone loss in mice results from a decrease in bone formation and an increase in cortical bone resorption. The former is accounted by a decrease in the number of postmitotic osteoblasts which synthesize the bone matrix and is thought to be the consequence of age‐dependent changes in mesenchymal osteoblast progenitors. However, there are no specific markers for these progenitors, and conclusions rely on results from in vitro cultures of mixed cell populations. Moreover, the culprits of such changes remain unknown. Here, we have used Osx1‐Cre;Td RFP mice in which osteoprogenitors express the Td RFP fluorescent protein. We report that the number of Td RFP ‐Osx1 cells, freshly isolated from the bone marrow, declines by more than 50% between 6 and 24 months of age in both female and male mice. Moreover, Td RFP ‐Osx1 cells from old mice exhibited markers of DNA damage and senescence, such as γH2 AX foci, G1 cell cycle arrest, phosphorylation of p53, increased p21 CIP 1 levels, as well as increased levels of GATA 4 and activation of NF ‐κ B – two major stimulators of the senescence‐associated secretory phenotype ( SASP ). Bone marrow stromal cells from old mice also exhibited elevated expression of SASP genes, including several pro‐osteoclastogenic cytokines, and increased capacity to support osteoclast formation. These changes were greatly attenuated by the senolytic drug ABT 263. Together, these findings suggest that the decline in bone mass with age is the result of intrinsic defects in osteoprogenitor cells, leading to decreased osteoblast numbers and increased support of osteoclast formation.